BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahri S, Rondon A, Wilms T, Bosquillon C, Vanbever R. Biodistribution and elimination pathways of PEGylated recombinant human deoxyribonuclease I after pulmonary delivery in mice. J Control Release 2021;329:1054-65. [PMID: 33091532 DOI: 10.1016/j.jconrel.2020.10.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Delfino D, Mori G, Rivetti C, Grigoletto A, Bizzotto G, Cavozzi C, Malatesta M, Cavazzini D, Pasut G, Percudani R. Actin-Resistant DNase1L2 as a Potential Therapeutics for CF Lung Disease. Biomolecules 2021;11:410. [PMID: 33802146 DOI: 10.3390/biom11030410] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Kunde SS, Ghosh R, Wairkar S. Emerging trends in pulmonary delivery of biopharmaceuticals. Drug Discov Today 2022:S1359-6446(22)00043-5. [PMID: 35143963 DOI: 10.1016/j.drudis.2022.02.003] [Reference Citation Analysis]
3 Mahri S, Hardy E, Wilms T, De Keersmaecker H, Braeckmans K, De Smedt S, Bosquillon C, Vanbever R. PEGylation of recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages. Int J Pharm 2021;593:120107. [PMID: 33259904 DOI: 10.1016/j.ijpharm.2020.120107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Li R, Jia Y, Kong X, Nie Y, Deng Y, Liu Y. Novel drug delivery systems and disease models for pulmonary fibrosis. J Control Release 2022;348:95-114. [PMID: 35636615 DOI: 10.1016/j.jconrel.2022.05.039] [Reference Citation Analysis]
5 Penaloza Arias LC, Huynh DN, Babity S, Marleau S, Brambilla D. Optimization of a Liposomal DNase I Formulation with an Extended Circulating Half-Life. Mol Pharm 2022. [PMID: 35543327 DOI: 10.1021/acs.molpharmaceut.2c00086] [Reference Citation Analysis]